What is Liveyon's Regenerative Medicine Product? 

It is an umbilical cord tissue/blood product that captures all the greatest regenerative properties of this otherwise discarded tissue. Our proprietary method of isolating growth factors, cells and stem cells gives the patient the best possible benefits from a regenerative medicine product. The use of cells, stem cells, and growth factors have all shown to be one of the best therapeutic methods to help aid in tissue healing and repair.   

Liveyon’s Commitment to Safety

Liveyon uses only umbilical cord-derived regenerative medicine products. This causes no pain for the patient as there is no extraction or procedure required to obtain the stem cell based product. Moreover, the product contains no known proteins that can cause a rejection in your patient. Research has shown that umbilical cord-derived stem cells are not susceptible to malignant transformation in a serum-free medium, making them safe for therapeutic use in patients.

Our regenerative medicine product are produced in a cGMP lab that receives all cord tissue/blood donations from hospitals directly to the facility, which guarantees minimal handling and a lower risk of cell loss or contamination. Our regenerative medicine product is produced in compliance with FDA cGMP (Current Good Manufacturing Practice) and GTP (Good Tissue Practices) standards, which assures you the end user quality and safety in our product. Most importantly, our regenerative medicine product is minimally manipulated preserving its natural healing properties.

Liveyon’s regenerative medicine product is easily shipped and once delivered yields consistent concentrations allowing for multiple administrations in uniform, high-cell-count doses. Patients can enjoy safe, non-surgical treatments in the time it would take them for a traditional office visit.    

Liveyon's ReGen® Series contains stem cells. Our characterized product contains mesenchymal stem cells (MSCs). These are defined by the stem cell marker CD90. Moreover, they are negative for HLA-DR which helps you feel comfortable that your patient will not have any negative reactions to the product.

Easy for Providers to Use and Administer

Liveyon ships its product directly from our facility to your medical practice. They are shipped frozen on dry ice, or in cryogenic dry vapor dewars.  Doctors receive our product in single-dose, uniform preparations, which means that no further manipulation is necessary, and it's easily administered.

Our Product is Guaranteed to meet or Exceed Specifications Listed

Our Product is Guaranteed to meet or Exceed Specifications Listed LIVEYON’s regenerative medicine product provides doctors with a specific concentration of cells listed on the product sheet. Moreover, we offer customizable quantities for individual applications. This makes you confident that you are delivering precisely a specific amount. We stand by our regenerative medicine product 100%.


Medical Professional Viewing Only (Disclaimer)

This site was intended for education purposes only and strictly for use by medical professionals. The FDA recently re-confirmed, there is only one registered stem cell product, and while there is enormous promise in stem cell therapies, and thousands of ongoing experimental applications trying to establish efficacy, these are not at the point where they would meet the scientific standard.

The FDA has stated:

Stem cells, like other medical products that are intended to treat, cure or prevent disease, generally require FDA approval before they can be marketed. FDA has not approved any stem cell-based products for use, other than cord blood-derived hematopoietic progenitor cells (blood forming stem cells) for certain indications.


This site is not intended for consumers.

If you are considering stem cell treatment in the U.S., ask your physician if the necessary FDA approval has been obtained or if you will be part of an FDA-regulated clinical study. This also applies if the stem cells are your own. Even if the cells are yours, there are safety risks, including risks introduced when the cells are manipulated after removal.

“There is a potential safety risk when you put cells in an area where they are not performing the same biological function as they were when in their original location in the body.” Cells in a different environment may multiply, form tumors, or may leave the site you put them in and migrate somewhere else.

If you are considering having stem cell treatment in another country, learn all you can about regulations covering the products in that country. Exercise caution before undergoing treatment with a stem cell-based product in a country that—unlike the U.S.—may not require clinical studies designed to demonstrate that the product is safe and effective. FDA does not regulate stem cell treatments used solely in countries other than the United States and typically has little information about foreign establishments or their stem cell products.


Stem cell therapies have enormous promise, but the science in each use is still in the developmental stage.  Professional judgment and expertise is needed in using stem cells for any therapeutic use, and we urge anyone embarking on the use of stem cell therapies to consult the national health data bases to evaluate current information from clinical trials and the FDA websites on human tissue should also be consulted to get its current evaluation of any therapy.